JH021
/ Biotech Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
July 23, 2026
An Open-label, Multicenter Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of JH021 Injection in Patients With Advanced Solid Tumors.
(ChiCTR)
- P1 | N=60 | Not yet recruiting | Sponsor: Shanghai East Hospital; Biotech Pharmaceutical Co., Ltd
New P1 trial • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor
1 to 1
Of
1
Go to page
1